Şunu aradınız:: myxoid liposarkom (Danca - İngilizce)

liposarkom
liposarcoma

studie 309 liposarkom-undergruppe
study 309 liposarcoma subgroup

studie 309 - progressionsfri overlevelse i liposarkom-undergruppen
study 309 – progression free survival in the liposarcoma subgroup

data vedrørende effekt er hovedsagelig baseret på patienter med liposarkom og leiomyosarkom.
efficacy data are based mainly on liposarcoma and leiomyosarcoma patients.

firmaet vil gennemføre en undersøgelse af virkningen af yondelis hos patienter med kræft af typen myksoidt liposarkom.
the company that makes yondelis will continue to assess which patients are more likely to respond to the medicine, and will carry out a study to investigate the effects of yondelis in patients with a type of cancer called ‘ myxoid liposarcoma’.

udvalget konstaterede, at dokumentationen for virkningerne af yondelis hovedsagelig bygger på behandling af liposarkom og leiomyosarkom.
the committee noted that evidence of yondelis’ s effects is mainly based on the treatment of liposarcoma and leiomyosarcoma.

halaven blev også undersøgt hos 143 patienter med liposarkom, som tidligere havde gennemgået mindst to andre behandlingsforløb med et antracyklinpræparat.
halaven was also studied in 143 patients with liposarcoma who had previously undergone at least two other treatments, which included an anthracycline.

desuden forlængede halaven overlevelsestiden for patienter med liposarkom, hvilket blev betragtet som vigtigt, da disse patienter har begrænsede behandlingsmuligheder.
additionally, halaven prolonged the length of time that liposarcoma patients lived, and this was considered important as these patients have limited treatment options.

virkningen og sikkerheden af trabectedin er baseret på et randomiseret forsøg med patienter med lokalt fremskredet eller metastatisk liposarkom eller leiomyosarkom, hvis sygdom havde udviklet sig eller var recidiveret efter behandling med antracykliner og ifosfamid som mindstekrav.
the efficacy and safety of trabectedin is based in a randomised trial in patients with locally advanced or metastatic liposarcoma or leiomyosarcoma, whose disease had progressed or relapsed after treatment with at least anthracyclines and ifosfamide.

dette bør omfatte et forslag til vurdering af yondelis ’ effekt og sikkerhed hos en undergruppe af patienter med myksoidt liposarkom, og det skal indsendes til emea inden 4. kvartal af 2007.
this should include a proposal to assess the efficacy and safety of yondelis in a sub-group of patients with myxoid liposarcoma and will be submitted to the emea by 4q 2007.

det firma, der fremstiller yondelis, vil fortsat vurdere, hvilke patienter medicinen forventes at virke bedst hos.firmaet vil gennemføre en undersøgelse af virkningen af yondelis hos patienter med kræft af typen myksoidt liposarkom.
the company that makes yondelis will continue to assess which patients are more likely to respond to the medicine, and will carry out a study to investigate the effects of yondelis in patients with a type of cancer called ` myxoid liposarcoma '.

det anvendes også hos voksne med fremskreden eller metastatisk liposarkom (en type cancer, der opstår fra fedtvævet), når tidligere behandling er prøvet, men ikke længere virker.
it is also used in adults for advanced or metastatic liposarcoma (a type of cancer that arises from fat tissue) when previous therapy has been tried but has lost its effect.

virkningerne af yondelis blev desuden undersøgt i en hovedundersøgelse med 266 patienter med liposarkom (et sarkom, der udgår fra fedtceller) eller leiomyosarkom (et sarkom, der udgår fra glatmuskulatur).
the effects of yondelis were also studied in one main study involving 266 patients with liposarcoma (a sarcoma originating in fat cells) or leiomyosarcoma (a sarcoma originating in ‘ smooth’ or involuntary muscle cells) that was advanced or metastatic (had spread to other parts of the body).